NEOS Investment Management LLC Purchases 4,140 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NEOS Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,650 shares of the biopharmaceutical company’s stock after buying an additional 4,140 shares during the quarter. NEOS Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,573,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. UniSuper Management Pty Ltd grew its stake in shares of Regeneron Pharmaceuticals by 38.0% during the 4th quarter. UniSuper Management Pty Ltd now owns 7,306 shares of the biopharmaceutical company’s stock worth $5,204,000 after acquiring an additional 2,013 shares in the last quarter. Sava Infond d.o.o. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $492,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 7.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,008 shares of the biopharmaceutical company’s stock valued at $127,118,000 after buying an additional 12,757 shares during the last quarter. Aviso Wealth Management lifted its position in Regeneron Pharmaceuticals by 65.1% during the 4th quarter. Aviso Wealth Management now owns 2,674 shares of the biopharmaceutical company’s stock worth $1,905,000 after buying an additional 1,054 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $316,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.9 %

REGN opened at $640.14 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a fifty day moving average of $685.91 and a 200-day moving average of $805.04. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20. The company has a market capitalization of $69.98 billion, a P/E ratio of 16.72, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 EPS. The business’s revenue was up 10.3% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent research reports. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, TD Cowen dropped their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.